Study of the efficacy and safety of the new drug "Efesovir" in comparison with the drug
"Remdesivir" in the treatment of patients hospitalized with COVID-19.
The hypothesis of clinical study is the clinical efficacy of new drug "Efesovir" is 10% to
30% higher than of "Remdesivir".
Phase:
Phase 2
Details
Lead Sponsor:
Scientific Center for Anti-infectious Drugs, Kazakhstan